Komentarze (30)
@Semicolon Mi bard ai mówi, że Dylotto to nowy lek na Alzheimera - ciągnie fejkiem.
cyt.
Dylotto is a new drug that is still under development. It is being developed for the treatment of Alzheimer's disease and other forms of dementia. Dylotto is a small molecule that works by inhibiting the production of amyloid beta, a protein that is thought to play a role in the development of Alzheimer's disease.
In preclinical studies, Dylotto has been shown to reduce the production of amyloid beta and to improve cognitive function in animal models of Alzheimer's disease. Dylotto is currently in Phase 1 clinical trials, which are the first human trials of a new drug. The purpose of Phase 1 clinical trials is to assess the safety and tolerability of the drug.
The results of the Phase 1 clinical trials of Dylotto have not yet been published. However, the company that is developing Dylotto has announced that the drug has been well-tolerated and that it has shown some promising signs of efficacy. The company is planning to initiate Phase 2 clinical trials of Dylotto in 2024.
It is important to note that Dylotto is still under development and has not yet been approved by the FDA for the treatment of any condition. More research is needed to determine the safety and efficacy of Dylotto in humans.
Zaloguj się aby komentować
